$3.82 Million in Sales Expected for Assembly Biosciences Inc (ASMB) This Quarter

Share on StockTwits

Equities research analysts forecast that Assembly Biosciences Inc (NASDAQ:ASMB) will announce sales of $3.82 million for the current quarter, according to Zacks. Four analysts have provided estimates for Assembly Biosciences’ earnings, with the highest sales estimate coming in at $4.29 million and the lowest estimate coming in at $2.70 million. Assembly Biosciences posted sales of $3.32 million during the same quarter last year, which suggests a positive year-over-year growth rate of 15.1%. The company is expected to issue its next earnings report on Thursday, March 14th.

On average, analysts expect that Assembly Biosciences will report full-year sales of $14.30 million for the current fiscal year, with estimates ranging from $12.00 million to $15.36 million. For the next fiscal year, analysts forecast that the company will post sales of $14.56 million, with estimates ranging from $12.00 million to $17.14 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.14. Assembly Biosciences had a negative return on equity of 50.63% and a negative net margin of 469.91%. The company had revenue of $4.29 million during the quarter, compared to the consensus estimate of $3.21 million.

A number of equities research analysts have recently weighed in on the company. Chardan Capital reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research note on Sunday, October 28th. BidaskClub raised Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 1st. Leerink Swann assumed coverage on Assembly Biosciences in a research note on Monday, November 19th. They set an “outperform” rating and a $45.00 price target for the company. Finally, Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Tuesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Assembly Biosciences has a consensus rating of “Buy” and an average target price of $52.00.

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Assembly Biosciences by 3.4% in the 4th quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock valued at $43,193,000 after acquiring an additional 63,554 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Assembly Biosciences by 29.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,051,454 shares of the biopharmaceutical company’s stock valued at $39,052,000 after acquiring an additional 238,952 shares in the last quarter. Vanguard Group Inc raised its stake in shares of Assembly Biosciences by 29.4% in the 3rd quarter. Vanguard Group Inc now owns 1,051,454 shares of the biopharmaceutical company’s stock valued at $39,052,000 after acquiring an additional 238,952 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Assembly Biosciences by 10.8% in the 3rd quarter. Janus Henderson Group PLC now owns 892,205 shares of the biopharmaceutical company’s stock valued at $33,136,000 after acquiring an additional 86,780 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of Assembly Biosciences by 3.4% in the 4th quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock valued at $12,009,000 after acquiring an additional 17,669 shares in the last quarter. 84.88% of the stock is currently owned by institutional investors and hedge funds.

Shares of ASMB traded up $0.26 during midday trading on Monday, reaching $22.75. 88,758 shares of the stock were exchanged, compared to its average volume of 203,795. Assembly Biosciences has a 12-month low of $18.58 and a 12-month high of $67.36. The company has a market capitalization of $572.67 million, a PE ratio of -9.44 and a beta of 1.37.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Featured Story: What is Cost of Debt?

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

NanoVibronix  & Its Rivals Head-To-Head Contrast
NanoVibronix & Its Rivals Head-To-Head Contrast
TJX Companies  Stock Rating Lowered by Zacks Investment Research
TJX Companies Stock Rating Lowered by Zacks Investment Research
HALFORDS GRP PL/ADR  Upgraded at Zacks Investment Research
HALFORDS GRP PL/ADR Upgraded at Zacks Investment Research
BP  PT Raised to GBX 600 at JPMorgan Chase & Co.
BP PT Raised to GBX 600 at JPMorgan Chase & Co.
Weight Watchers International  Price Target Cut to $99.00 by Analysts at Sidoti
Weight Watchers International Price Target Cut to $99.00 by Analysts at Sidoti
Zogenix Sees Unusually High Options Volume
Zogenix Sees Unusually High Options Volume


Leave a Reply

 
© 2006-2019 Zolmax.